Retatrutide is a new treatment in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By stimulating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately results in significant reduction in body mass. While research is